146 related articles for article (PubMed ID: 18006782)
21. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.
Jäger E; Jäger D; Karbach J; Chen YT; Ritter G; Nagata Y; Gnjatic S; Stockert E; Arand M; Old LJ; Knuth A
J Exp Med; 2000 Feb; 191(4):625-30. PubMed ID: 10684854
[TBL] [Abstract][Full Text] [Related]
22. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
[TBL] [Abstract][Full Text] [Related]
23. Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE.
Miyahara Y; Naota H; Wang L; Hiasa A; Goto M; Watanabe M; Kitano S; Okumura S; Takemitsu T; Yuta A; Majima Y; Lemonnier FA; Boon T; Shiku H
Clin Cancer Res; 2005 Aug; 11(15):5581-9. PubMed ID: 16061876
[TBL] [Abstract][Full Text] [Related]
24. Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells.
Dao T; Korontsvit T; Zakhaleva V; Haro K; Packin J; Scheinberg DA
PLoS One; 2009 Aug; 4(8):e6730. PubMed ID: 19707583
[TBL] [Abstract][Full Text] [Related]
25. Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein.
Parkhurst MR; Riley JP; Robbins PF; Rosenberg SA
J Immunother; 2004; 27(2):79-91. PubMed ID: 14770079
[TBL] [Abstract][Full Text] [Related]
26. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
Zarour HM; Storkus WJ; Brusic V; Williams E; Kirkwood JM
Cancer Res; 2000 Sep; 60(17):4946-52. PubMed ID: 10987311
[TBL] [Abstract][Full Text] [Related]
27. Generation of mammaglobin-A-specific CD4 T cells and identification of candidate CD4 epitopes for breast cancer vaccine strategies.
Viehl CT; Frey DM; Phommaly C; Chen T; Fleming TP; Gillanders WE; Eberlein TJ; Goedegebuure PS
Breast Cancer Res Treat; 2008 May; 109(2):305-14. PubMed ID: 17653857
[TBL] [Abstract][Full Text] [Related]
28. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.
Tatsumi T; Kierstead LS; Ranieri E; Gesualdo L; Schena FP; Finke JH; Bukowski RM; Mueller-Berghaus J; Kirkwood JM; Kwok WW; Storkus WJ
J Exp Med; 2002 Sep; 196(5):619-28. PubMed ID: 12208877
[TBL] [Abstract][Full Text] [Related]
29. MAGE-A3(161-175) contains an HLA-DRbeta4 restricted natural epitope poorly formed through indirect presentation by dendritic cells.
Marturano J; Longhi R; Casorati G; Protti MP
Cancer Immunol Immunother; 2008 Feb; 57(2):207-15. PubMed ID: 17628799
[TBL] [Abstract][Full Text] [Related]
30. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.
Mandic M; Almunia C; Vicel S; Gillet D; Janjic B; Coval K; Maillere B; Kirkwood JM; Zarour HM
Cancer Res; 2003 Oct; 63(19):6506-15. PubMed ID: 14559844
[TBL] [Abstract][Full Text] [Related]
31. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.
Kobayashi H; Song Y; Hoon DS; Appella E; Celis E
Cancer Res; 2001 Jun; 61(12):4773-8. PubMed ID: 11406551
[TBL] [Abstract][Full Text] [Related]
32. A MAGE-1 peptide recognized on HLA-DR15 by CD4(+) T cells.
Chaux P; Lethé B; Van Snick J; Corthals J; Schultz ES; Cambiaso CL; Boon T; van der Bruggen P
Eur J Immunol; 2001 Jun; 31(6):1910-6. PubMed ID: 11433388
[TBL] [Abstract][Full Text] [Related]
33. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D
Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643
[TBL] [Abstract][Full Text] [Related]
34. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
[TBL] [Abstract][Full Text] [Related]
35. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.
Zeng G; Touloukian CE; Wang X; Restifo NP; Rosenberg SA; Wang RF
J Immunol; 2000 Jul; 165(2):1153-9. PubMed ID: 10878395
[TBL] [Abstract][Full Text] [Related]
36. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
[TBL] [Abstract][Full Text] [Related]
37. The CD4+ T-cell epitope-binding register is a critical parameter when generating functional HLA-DR tetramers with promiscuous peptides.
Cecconi V; Moro M; Del Mare S; Sidney J; Bachi A; Longhi R; Sette A; Protti MP; Dellabona P; Casorati G
Eur J Immunol; 2010 Jun; 40(6):1603-16. PubMed ID: 20306469
[TBL] [Abstract][Full Text] [Related]
38. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes.
Oiso M; Eura M; Katsura F; Takiguchi M; Sobao Y; Masuyama K; Nakashima M; Itoh K; Ishikawa T
Int J Cancer; 1999 May; 81(3):387-94. PubMed ID: 10209953
[TBL] [Abstract][Full Text] [Related]
39. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes.
Schultz ES; Lethé B; Cambiaso CL; Van Snick J; Chaux P; Corthals J; Heirman C; Thielemans K; Boon T; van der Bruggen P
Cancer Res; 2000 Nov; 60(22):6272-5. PubMed ID: 11103782
[TBL] [Abstract][Full Text] [Related]
40. A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein.
Zhang Y; Chaux P; Stroobant V; Eggermont AM; Corthals J; Maillère B; Thielemans K; Marchand M; Boon T; Van Der Bruggen P
J Immunol; 2003 Jul; 171(1):219-25. PubMed ID: 12817001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
